Novel sulphonamide derivatives for the treatment of cancer

Expert Opinion on Therapeutic Patents

Volumn 10, Issue 11, 2000, Pages 1725-1740

  Owa, T ^a   Nagasu, T ^a  

^a EISAI CO LTD   (Japan)

Author keywords

Angiogenesis; Anti tumour; Antimitotic; Carbonic anhydrase; Cell cycle; G1 phase; M phase; NF Y; Sulphonamide; Sulphonylurea; Tubulin; Xenograft

Indexed keywords

1 (3,4 DICHLOROPHENYL) 3 (2,3 DIHYDROBENZOFURAN 5 YLSULFONYL)UREA; ACETAZOLAMIDE; ANTIBIOTIC AGENT; ANTIDIABETIC AGENT; ANTIGLAUCOMA AGENT; ANTINEOPLASTIC AGENT; CARBONATE DEHYDRATASE INHIBITOR; CHLOROQUINOXALINE SULPHONAMIDE; DIURETIC AGENT; E 34410; E 6820300; ETHOXZOLAMIDE; FUROSEMIDE; HMN 154; HMN 176; HMN 214; INDISULAM; METHAZOLAMIDE; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; NUCLEAR FACTOR Y; PACLITAXEL; PENTAFLUOROBENZENESULPHONAMIDE; SULFAMIDOCHRYSOIDINE; SULFANILAMIDE; SULFONAMIDE; SULOFENUR; T 138067; T 900607; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIHYPERTENSIVE ACTIVITY; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE G1 PHASE; CLINICAL TRIAL; CONFORMATIONAL TRANSITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CONFORMATION; DRUG MECHANISM; DRUG SCREENING; DRUG SYNTHESIS; ENZYME INHIBITION; GROWTH INHIBITION; HEMOLYTIC ANEMIA; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; METHEMOGLOBINEMIA; MICROTUBULE ASSEMBLY; MOUSE; NEUROPATHY; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RAT; REVIEW; STRUCTURE ACTIVITY RELATION; SUPRAVENTRICULAR TACHYCARDIA; TRANSCRIPTION REGULATION;

EID: 0033765660     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.10.11.1725     Document Type: Review

References (102)

1. Relations between structure and biological activity of sulfonamides
2. Carbonic anhydrase inhibitors
3. Drug discovery: A historical perspective
4. Sulfonylurea receptors, ion channels and fruit flies
5. Isosterism and molecular modification in drug design
6. The discovery and structure-activity relationships of nonpeptide, low molecular weight antagonists selective for the endothelin ET(B) receptor
7. Endothelin antagonists: Substituted mesitylcarboxamides with high potency and selective for ET(A) receptors
8. 6 receptors
9. 6 receptor antagonist
10. 3 adrenergic receptor agonists containing imidazolidinone and imidazolone benzenesulfonamides
11. 3 adrenergic receptor agonists containing a substituted indoline-5-sulfonamide pharmacophore
12. Diaryl-sulfonamides as selective, non-peptidic thrombin inhibitors
13. C6 modification of the pyridinone core of thrombin inhibitor L-374,087 as a means of enhancing its oral absorption
14. Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors
15. Protease inhibitors. Part 8: Synthesis of potent Clostridium histolyticum collagenase inhibitors incorporating sulfonylated l-alanine hydroxamate moieties
16. New approaches to anti-tumor drug screening: The human tumor colony-forming assay
17. Chloroquinoxaline sulfonamide: A sulfanilamide anti-tumor agent entering clinical trials
18. Evaluation of in vitro drug screening leads using experimental models of human ovarian cancer
19. Cellular pharmacology of chloroquinoxaline sulfonamide and a related compound in murine B16 melanoma cells
20. Immunosuppressive properties of chloroquinoxaline sulfonamide
21. Phase I clinical and pharmacological study of chloroquinoxaline sulfonamide
22. Phase I trial of chloroquinoxaline sulfonamide, with correlation of its pharmacokinetics and pharmacodynamics
23. Clinical and pharmacology study of chloroquinoxaline sulfonamide given on a weekly schedule
24. Phase II trial of chloroquinoxaline sulfonamide (CQS) in patients with stage III and IV non-small-cell lung cancer
25. Data display and analysis strategies from NCI disease-oriented in vitro anti-tumor drug screen
26. Some practical considerations and applications of the NCI in vitro anticancer drug discovery screen
27. Novel agents effective against solid tumors: The diarylsulfonylureas. Synthesis, activities and analysis of quantitative structure-activity relationships
28. Sulofenur cytotoxicity and changes in cytosolic calcium and mitochondrial membrane potential in human colon adenocarcinoma cell lines
29. Studies on the mechanism of sulofenur and LY295501 toxicity: Effect on the regulation of cytosolic calcium in relation to cytotoxicity in normal and tumorigenic rat kidney cell lines
30. Effect of anti-tumor diarylsulfonylureas on in vivo and in vitro mitochondrial structure and functions
31. Effect of diarylsulfonylurea anti-tumor agents on the function of mitochondria isolated from rat liver and GC3/c1 cells
32. The anti-tumor sulfonylurea N-(4-methylphenylsulfonyl)-N'-(4-chlorophenyl)urea (LY181984) inhibits NADH oxidase activity of HeLa plasma membranes
33. A circulating form of NADH oxidase activity responsive to the anti-tumor sulfonylurea N-(4-methylphenylsulfonyl)-N'-(4-chloro phenyl)urea (LY181984) specific to sera from cancer patients
34. The sulfonylurea-inhibited NADH oxidase activity of HeLa cell plasma membranes has properties of a protein disulfide-thiol oxidoreductase with protein disulfidethiol interchange activity
35. H-ras transfection of the rat kidney cell line NRK-52E results in increased induction of c-fos, c-jun and hsp70 following sulofenur treatment
36. Characterization of the intracellular distribution and binding in human adenocarcinoma cells of N-(4-azidophenylsulfonyl)-N'-(4-chloro phenyl)urea (LY219703), a photoaffinity analogue of the anti-tumor diarylsulfonylurea sulofenur
37. Identification of anti-tumor sulfonylurea binding protein of HeLa plasma membranes
38. Impermeant anti-tumor sulfonylurea conjugates that inhibit plasma membrane NADH oxidase and growth of HeLa cells in culture. Identification of binding proteins from sera of cancer patients
39. Proliferation-dependent and -independent cytotoxicity by anti-tumor diarylsulfonylureas. Indication of multiple mechanisms of drug action
40. Anti-tumor diarylsulfonylureas: Novel agents with unfulfilled promise
41. Sulfonylureas: A new class of cancer chemotherapeutic agents
42. Sulfonimidamide analogs of oncolytic sulfonylureas
43. Synthesis and cytotoxic evaluation of substituted sulfonyl-N-hydroxyguanidine derivatives as potential anti-tumor agents
44. Efficacy of sulofenur and a second generation diarylsulfonylurea, N-[5-(2,3-dihydrobenzofuryl)sulfonyl]-N-(3,4-dichlor ophenyl)urea (LY295501), against colon adenocarcinoma xenografts
45. Evaluation of 5-(indanylsulfonyl)-N-(4-chlorophenyl)urea against xenografts of pediatric rhabdomyosarcoma
46. Clinical pharmacology of a novel diarylsulfonylurea anticancer agent
47. Phase I trial of sulofenur (LY186641) given orally on a daily x 21 schedule
48. Phase I and pharmacokinetic study of LY186641 administered daily for 2 weeks every 21 days
49. Phase II study of sulofenur (LY186641) in untreated patients with extensive small cell lung cancer
50. Phase II study of sulofenur (LY186641) in measurable metastatic renal cancer
51. A Phase II study of sulofenur (LY186641) in gastric cancer
52. A Phase II study of sulofenur, a novel sulfonylurea, in recurrent epithelial ovarian cancer
53. Phase II trial of the novel sulphonylurea sulofenur in advanced breast cancer
54. Phase II study of sulofenur (LY186641). A novel antineoplastic agent in advanced non-small cell lung cancer
55. Phase II evaluation of the sulfonylurea LY186,641 in men with hormone independent metastatic prostate cancer
56. Phase II trial of LY186641 in advanced renal cancer
57. Anti-tumor activity and clinical pharmacology of sulofenur in ovarian cancer
58. Pharmacokinetics of the anticancer agent sulofenur in mice, rats, monkeys and dogs
59. Kinetics of N-[(4-chlorophenyl)amino]carbonyl-2,3-dihydro-1H-indene-5-sulfonamide (LY186641) in humans
60. Significant activity of a novel cytotoxic agent, LY295501, against a wide range of tumors in the human tumor cloning system
61. Evaluation of new anticancer agents against the MIA PaCa-2 and PANC-1 human pancreatic carcinoma xenografts
62. Efficacy of sulofenur and a second generation diarylsulfonylurea, N-[5-(2,3-dihydrobenzofuryl)sulfonyl]-N'-(3,4-dichlor ophenyl)urea (LY295501), against colon adenocarcinoma xenografts
63. Phase I trial of the diarylsulfonylurea LY295501 administered on a weekly x 3 schedule
64. Phase I trial of the diarylsulfonylurea LY295501 administered orally once daily for 5 days every 28 days
65. Phase I and pharmacokinetic (PK) study of the diarylsulfonylurea LY295501 administered as a single oral dose weekly for 3 weeks every 4 weeks
66. Novel sulfonamides as potential, systemically active anti-tumor agents
67. Mechanism of action of E7010, an orally active sulfonamide anti-tumor agent: Inhibition of mitosis by binding to the colchicine site of tubulin
68. Preferential binding of E7010 to murine beta 3-tubulin and decreased beta 3-tubulin in E7010-resistant cell lines
69. E7010, a novel sulfonamide anti-tumor agent. IV. Pharmacokinetics and metabolic fate Proc.
70. In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors
71. Phase I study of E7010
72. ER-34410, a structurally novel sulfonamide as a potential and injectable anti-tumor agent
73. A focused compound library of novel N-(7-indolyl)benzenesulfonamides for the discovery of potent cell cycle inhibitors
74. A novel anti-tumor agent ER-35744, targeting G1 phase. I. Discovery and structure-activity relationships
75. Discovery of novel anti-tumor sulfonamides targeting G1 phase of the cell cycle
76. A novel anti-tumor agent ER-35744, targeting G1 phase. II. anti-tumor activities in vitro and in vivo
77. Anti-tumor effect of E7070 (ER-35744) against orthotopically transplanted mouse and human colorectal tumors
78. A novel anti-tumor agent ER-35744, targeting G1 phase. III. Studies of mechanism of action
79. Phase I and pharmacokinetic study of E7070 in patients with solid tumors as single iv infusion, weekly x 4, q 6 weeks
80. Phase I trial of five-days continuous infusion E7070 [N-(3-chloro-7-indolyl)-1,4-benzenedisulfonamide] in patients (pts) with solid tumors
81. Phase I and pharmacokinetic (PK) study of E7070, a novel sulphonamide, given daily x 5 every 3 weeks as a 1-hour intravenous infusion in patients (pts) with advanced solid tumors
82. Phase I and pharmacokinetic (PK) study of E7070, a new chloroindolylsulfonamide, given as a 1-hour infusion every 3 weeks in patients (pts) with advanced solid tumors
83. A novel angiogenesis inhibitor, ER-68203-00, I. A new mode of action
84. A novel angiogenesis inhibitor, ER-68203-00, II. Anti-angiogenesis potency and therapeutic efficacy in tumor xenograft models
85. Mode and mechanisms of cell death induced by HMN-214, a novel anti-tumor sulfonamide compound
86. Apoptosis induced by novel anti-cancer compound, HMN-154 (HMN-176) through suppressing the expression of cell cycle controllers
87. HMN-214, a novel anti-tumor sulfonamide compound
88. Novel antineoplastic agents with efficacy against multidrug resistant tumor cells
89. Selective, covalent modification of β-tubulin residue Cys-239 by T138067, an anti-tumor agent with in vivo efficacy against multidrug-resistant tumors
90. Novel halogenated sulfonamides inhibit the growth of multidrug resistant MCF-7/ADR cancer cells
91. Selective, covalent modification of certain β-tubulin isotypes by T900607, a novel anti-tumor agent with efficacy against multidrug resistant tumors
92. Pharmacokinetics of T900607 in preclinical species
93. Carbonic anhydrase inhibitors and their therapeutic potential
94. A carbonic anhydrase inhibitor as a potential modulator of cancer therapies
95. Carbonic anhydrase and cancer
96. Sulphonamide inhibitors of carbonic anhydrase inhibit the growth of human lymphoma cells in culture
97. Carbonic anhydrase inhibitors: Sulfonamides as anti-tumor agents?
98. Carbonic anhydrase inhibitors: Synthesis of N-morpholythiocarbonylsulfenylamino aromatic/heterocyclic sulfonamides and their interaction with isozymes I, II and IV
99. Carbonic anhydrase inhibitors: Aromatic sulfonamides and disulfonamides act as efficient tumor growth inhibitors
100. Carbonic anhydrase inhibitors - Part 94. 1,3,4-Thiadiazole-2-sulfonamide derivatives as anti-tumor agents?
101. Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes
102. Carbonic anhydrase inhibitor suppresses invasion of renal cancer cells in vitro